Main
cancer death, PDAC, autogene cevumeran
PDAC is the third leading cause of cancer death in the United StatesPDACs are almost completely insensitive (<5% response rateBased on the observation that long-term survivors of PDAC mount spontaneous T cell responses against tumour-specific neoantigens not shared among patientsTo test this hypothesis, we conducted an investigator-initiated, phase I clinical trial of sequential adjuvant atezolizumab (Genentech), autogene cevumeran